CoChat

Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis

Karikoski, Marika, Marttila-Ichihara, Fumiko, Elima, Kati, Rantakari, Pia, Hollmén, Maija, Kelkka, Tiina, Gerke, Heidi, Huovinen, Ville, Irjala, Heikki, Holmdahl, Rikard, Salmi, Marko, Jalkanen, Sirpa · 2014 · Clinical Cancer Research
Cited by 98

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: Immunosuppressive leukocytes and vasculature are important host cell components regulating tumor progression. Clever-1/Stabilin-1, a multifunctional scavenger and adhesion receptor, is constitutively present on a subset of type II macrophages and lymphatic endothelium, but its functional role in cancer is unknown. Experimental Design: Here, we generated full Clever-1 knockout mice and cell-specific ones lacking Clever-1 either on macrophages or endothelium. We also used anti-Clever-1 antibody therapy to treat B16 melanoma and EL-4 lymphoma. Results: Clever-1–deficient mice had smaller primary and metastatic tumors than wild-type (WT) controls. Growth of primary tumors, but not of metastases, was attenuated also in mice lacking Clever-1 selectively in macrophages or in vascular endothelium. Anti-Clever-1 antibody treatment inhibited tumor progression in WT mice. Both genetically and therapeutically induced absence of functional Clever-1 led to diminished numbers of immunosuppressive leukocyte types in tumors. Functionally Clever-1 mediated binding of immunosuppressive leukocytes to the intratumoral blood vessels aberrantly expressing Clever-1, and tumor cell traffic via the lymphatics. The antibody therapy did not aggravate autoimmunity. Conclusion: This work identifies Clever-1 in type II macrophages and in tumor vasculature as a new immunosuppressive molecule in cancer. Our finding that Clever-1 supports binding of tumor-infiltrating lymphocytes to tumor vasculature increases our understanding of leukocyte immigration to tumors. The ability of anti-Clever-1 antibody treatment to attenuate tumor progression in WT mice in vivo is therapeutically relevant. Thus, Clever-1 may be an emerging new target for modulating immune evasion and lymphatic spread in cancer. Clin Cancer Res; 20(24); 6452–64. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1236

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 98

Metadata

Authors
Karikoski, M., Marttila-Ichihara, F., Elima, K., Rantakari, P., Hollmén, M., Kelkka, T., Gerke, H., Huovinen, V., Irjala, H., Holmdahl, R., Salmi, M., & Jalkanen, S.
Venue
Clinical Cancer Research
Published
2014-12-14
Volume
20
Issue
24
Pages
6452-6464
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2092586559
Cited by
98
References
2
FWCI
1.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1236
The paper
Karikoski, M., Marttila-Ichihara, F., Elima, K., Rantakari, P., Hollmén, M., Kelkka, T., Gerke, H., Huovinen, V., Irjala, H., Holmdahl, R., Salmi, M., & Jalkanen, S. (2014). Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1236

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.